Skip to main content
Premium Trial:

Request an Annual Quote

Product Watch: Thermo Fisher QuantStudio 3D Rare Mutation Analysis


Thermo Fisher Scientific this week announced the release of the QuantStudio 3D Rare Mutation Analysis solution.

The new offering is a panel of wet-lab validated TaqMan SNP genotyping assays and an enhanced software tool that enables researchers to detect and quantify 40 of the most common mutations in cancer genes, including EGFR, BRAF, KRAS, PIK3CA, and JAK2, at a prevalence as low as 0.1 percent.

The primary and secondary software enhancements are also designed with specific features for analysis of low-frequency alleles on the QuantStudio 3D Digital PCR system.

"Our laboratory is investigating methods to quantify the presence of mutations in cancer-related genes in circulating free DNA," Atocha Romero, a researcher in the Molecular Oncology Laboratory of Hospital Clinico San Carlos in Madrid, Spain, said in a statement. "We have tested the PIK3CA H1047R Custom TaqMan SNP Genotyping Assay on the QuantStudio 3D Digital PCR System, and we have observed that the sensitivity we can achieve with this assay is far superior than with other approaches. This assay meets all of our requirements for quantifying low-frequency mutations in circulating-free DNA."

The QuantStudio 3D system and new assays are for research use only.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.